Abstract
This article explores an alternative understanding of how psychiatric drugs work that is referred to as the “drug-centred” model of drug action. Unlike the standard “disease-centred” model, which suggests that psychiatric drugs work by correcting an underlying brain abnormality, the drug-centred model emphasises how psychiatric drugs affect mental states and behaviour by modifying normal brain processes. The alterations produced are superimposed on the emotional and behavioural problems that constitute the symptoms of mental disorders. The chapter examines research into drug action to show the dearth of support for the disease-centred model. It then explores the clinical implications of adopting a drug-centred model of drug action. This requires a detailed understanding of the mental and physical alterations produced by individual drugs and an exploration of how those alterations might interact with particular sets of symptoms and problems. Drug-centred approaches to the drug treatment of psychosis and depression are presented as examples. It is concluded that any benefits due to being in an altered state need to be carefully balanced against the damage that may occur with long-term exposure and that we need further research to elucidate all the consequences of using drugs in this way.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abse DW, Dahlstrom WG, Tolley AG. Evaluation of tranquilizing drugs in the management of acute mental disturbance. Am J Psychiatr. 1960;116:973–80. Available from: PM:13791594
Alexander J, Tharyan P, Adams C, John T, Mol C, Philip J. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v haloperidol plus promethazine. Br J Psychiatry. 2004;185:63–9. Available from: PM:15231557
American Psychiatric Association. Lets talk facts about depression. Ref type: pamphlet. Washington, DC; 2005.
Berridge CW. Neural substrates of psychostimulant-induced arousal. Neuropsychopharmacology. 2006;31(11):2332–40. Available from: PM:16855535
Bourin M, Fiocco AJ, Clenet F. How valuable are animal models in defining antidepressant activity? Hum Psychopharmacol. 2001;16(1):9–21. Available from: PM:12404593
Braden W, Fink EB, Qualls CB, Ho CK, Samuels WO. Lithium and chlorpromazine in psychotic inpatients. Psychiatry Res. 1982;7(1):69–81. Available from: PM:6813888
Breggin P. Brain-disabling treatments in psychiatry. 2nd ed. New York: Springer Publishing Company; 2008.
Casey JF, Bennett IF, Lindley CJ, Hollister LE, Gordon MH, Springer NN. Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo. Arch Gen Psychiatry. 1960a;2:210–20. Available from: PM:13808145
Casey JF, Lasky JJ, Klett CJ, Hollister LE. Treatment of schizophrenic reactions with phenothiazine derivatives. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine, and phenobarbital. Am J Psychiatr. 1960b;117:97–105. Available from: PM:13808146
Chouinard G. The use of benzodiazepines in the treatment of manic-depressive illness. J Clin Psychiatry. 1988;49(Suppl):15–20. Available from: PM:2903143
Dubovsky SL, Davies R, Dubovsky AN. Mood Disorders. In: Hales RE, Yudofsky SC, editors. Textbook of clinical psychiatry. Washington, DC: American Psychiatric Association; 2001.
Eli Lilly. (2006) Zyprexa website. www.zyprexa.com/bipolar/treating.asp. 7-12-2006. Ref type: electronic citation.
Farnsworth KD, Dinsmore WW. Persistent sexual dysfunction in genitourinary medicine clinic attendees induced by selective serotonin reuptake inhibitors. Int J STD & AIDS. 2009;20(1):68–9. Available from: PM:19103903
Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72–81. Available from: PM:25721705
Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatr. 1996;153(2):151–62. Available from: PM:8561194
Johnstone EC, Crow TJ, Frith CD, Owens DG. The Northwick Park “functional” psychosis study: diagnosis and treatment response. Lancet. 1988;2(8603):119–25. Available from: PM:2899186
Judd LL, Hubbard B, Janowsky DS, Huey LY, Attewell PA. The effect of lithium carbonate on affect, mood, and personality of normal subjects. Arch Gen Psychiatry. 1977a;34(3):346–51. Available from: PM:320956
Judd LL, Hubbard B, Janowsky DS, Huey LY, Takahashi KI. The effect of lithium carbonate on the cognitive functions of normal subjects. Arch Gen Psychiatry. 1977b;34(3):355–7. Available from: PM:320957
Kendler KS, Schaffner KF. The dopamine hypothesis of schizophrenia: an historical and philosophical analysis. Philos Psychiatry Psychol. 2011;18:41–63.
Mizrahi R, Bagby RM, Zipursky RB, Kapur S. How antipsychotics work: the patients’ perspective. Prog Neuro-Psychopharmacol Biol Psychiatry. 2005;29(5):859–64. Available from: PM:15908094
Moncrieff J. Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Disord. 2001;189(5):288–95. Available from: PM:11379971
Moncrieff J. The myth of the chemical cure: a critique of psychiatric drug treatment. Basingstoke: Palgrave Macmillan; 2008.
Moncrieff J. A critique of the dopamine hypothesis of schizophrenia and psychosis. Harv Rev Psychiatry. 2009;17(3):214–25. Available from: PM:19499420
Moncrieff J. Antipsychotic maintenance treatment: time to rethink? PLoSMed. 2015;12(8):e1001861. Available from: PM:26241954
Moncrieff J, Cohen D. Rethinking models of psychotropic drug action. Psychother Psychosom. 2005;74(3):145–53. Available from: PM:15832065
Moncrieff J, Cohen D. Do antidepressants cure or create abnormal brain states? PLoS Med. 2006;3(7):e240. Available from: PM:16724872
Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of internet data. Acta Psychiatr Scand. 2009;120(2):102–11. Available from: PM:19222405.
Moncrieff J, Kirsch I. Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences. Contemp Clin Trials. 2015;43:60–2. Available from: PM:25979317
Murphy FC, Smith KA, Cowen PJ, Robbins TW, Sahakian BJ. The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. Psychopharmacology. 2002;163(1):42–53. Available from: PM:12185399
Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, Di Forti M, Taylor D. Should psychiatrists be more cautious about the long-term use of antipsychotics? Br J Psychiatry. 2016;209:361–5.
Prien RF, Caffey EM Jr, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry. 1972;26(2):146–53. Available from: PM:4551257
Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord. 1982;4(3):173–93. Available from: PM:6127357
Royal College of Psychiatrists. Antidepressants. London: Royal College of Psychiatrists; 2009. Ref type: pamphlet.
Sharma T, Guski LS, Freund N, Gotzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. Br Med J. 2016;352:i65. Available from: PM:26819231
Stahl SM. Stahl’s essential psychopharmacology. 4th ed. Cambridge: Cambridge University Press; 2013.
Tschanz JT, Rebec GV. Atypical antipsychotic drugs block selective components of amphetamine-induced stereotypy. Pharmacol Biochem Behav. 1988;31(3):519–22. Available from: PM:3251235
Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatr. 1991;148(6):714–26. Available from: PM:1674645
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Moncrieff, J. (2019). An Alternative Approach to Drug Treatment in Psychiatry. In: Steingard, S. (eds) Critical Psychiatry. Springer, Cham. https://doi.org/10.1007/978-3-030-02732-2_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-02732-2_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-02731-5
Online ISBN: 978-3-030-02732-2
eBook Packages: MedicineMedicine (R0)